20 February 2020 - The global
Drug Discovery Informatics Market
is projected to grow at a CAGR of 12.6% over the forecast period. Drug
discovery is a multidisciplinary process used by researchers to encounter
highly interconnected and complex meta data with the unprecedented availability
of instrumentation and information technology. It is a capital-intensive,
complicated, and a lengthy procedure, which demands expertise from
pharmaceutical and multiple other scientific disciplines.
“The advanced information
technology has redefined the traditional drug discovery process and the
research productivity of computational chemistry application is providing
substantial benefits to drug discovery informatics platform.”
Inexpensive computing is
transforming the face of modern discovery informatics. The redefinition of drug
discovery informatics is serving scientists with decision support tools and the
rise in data culture is driving the growth of drug discovery informatics
market.
Presently, the industry is
facing major productivity challenges to efficiently generate pipelined products
to replace the fading blockbusters of genomics. The rising research &
development expenses and downward pricing pressures have emerged a potential
threat to the industry growth. The swelling regulatory burden and lack of a
worldwide governing harmony have added up to the challenges faced by the
pharmaceutical vendors. The new entrants are increasingly organizing
cross-functional working groups to evaluate the authenticity of these
applications and methods to steer these methodologies for their unique
discovery process. In an attempt to minimize cost restraints, the market
players have found new technologies resulting in a shift from conventional
methodologies towards modern-day technologies.
By process type, the drug
discovery informatics market has found its segments across Sequencing &
Target Data Analysis, Screening & ADMET characterization, Docking,
Libraries & Database Preparation, and Molecular Modelling among others.
Software and services have been identified as the key bifurcation of the
solution segment of the market. Further breakdown of the end-user industry
includes contract research organizations (CROs), pharmaceutical &
biotechnology companies, and others (academic institutes and government
organizations).
Furthermore, the industry
players are increasing their investments to incorporate innovative service
launches in order to enhance their prominence and survive the competitive edge.
Drug development, marketing and its commercialization have been attributed has
expensive and demands huge investments.
The increasing requirement of
drugs to treat several diseases has propelled a number of merger and
acquisition (M&A) activities aiming to meet complicated test targets. The
drug discovery informatics have helped researches to make better decisions
related to higher human anatomy. The big pharma companies are supplementing
their overall drug discovery and delivery process by leveraging key
competencies like partnerships and outsourcing their research activities to the
organizations whose risk assessment are more compatible with financial
structures. The industry participants are focusing on core competencies to
foster efficient collaborations by outsourcing the areas that appear to be too
risky and unclear.
The quest for enhanced efficiency
of Drug Discovery, led to formation of ‘rational drug design’ in the 1980s. The
development of operational informatics has propelled the concept of agile
laboratory for chemical registration and IT systems that manages the flow of
chemicals throughout the lab.
The competitive landscape
showcases the profiles and business strategies of the major players, along with
their recent developments. Some of the dominant players operating in this
market include Thermo Fisher Scientific, Charles River Laboratories
International, Inc., PerkinElmer Inc., Boehringer Ingelheim GmbH, Biogen Inc.,
Insilico Medicine, Inc., Schrödinger, International Business Machines
Corporation, LLC, Certara, L.P, and Albany Molecular Research Inc. (AMRI) among
others. In terms of sustainability and standardization, the drug discovery
informatics market is opening new opportunities for savvy entrants to
capitalize on the growing demand.
Market Segment:
Drug Discovery Informatics Workflow Outlook (Revenue, USD Million, 2014
- 2025)
• Discovery Informatics
• Identification & Validation
Informatics Assay Development Informatics
• Lead Generation Informatics
• Development Informatics
• Lead Optimization
• FHD Preparation
• Phase IA Informatics
• Phase IB/2 Informatics
Drug Discovery Informatics Mode Outlook (Revenue, USD Million, 2014 -
2025)
• In-house Informatics
• Outsourced Informatics
Drug Discovery Informatics Service Outlook (Revenue, USD Million, 2014
- 2025)
• Sequence Analysis Platforms
• Molecular Modeling
• Docking
• Clinical Trial Data Management
• Others
Drug Discovery Informatics Regional Outlook (Revenue, USD Million, 2014
- 2025)
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• Asia Pacific
• China
• Japan
• Latin America
• Brazil
Comments
Post a Comment